The effectiveness of ixekizumab and other bDMARDs at 12-months for patients with PsA in real-world settings: Results from the PRO-SPIRIT study
Introduction: GRAPPA and EULAR recommendations highlight the importance of individualised psoriatic arthritis (PsA) treatment and suggest treatment target should be clinical remission (REM) or low/minimal disease activity (LDA/MDA) across key PsA domains [ref:1], [ref:2]. [for full text, please go to the a.m. URL]
Institutions
- University of Copenhagen (DK)
- University of Leeds (GB)
- Eli Lilly (United States) (US)
- University College Copenhagen (DK)
- Düsseldorf University Hospital (DE)
- German Rheumatism Research Centre (DE)
- Schlosspark-Klinik (DE)
- Orthopädische Praxis (DE)
Publication Details
- Journal
- German Medical Science (German Research Foundation)
- Published
- 2024-09-18
- DOI
- https://doi.org/10.3205/24dgrh177
- Primary Topic
- Spondyloarthritis Studies and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00